Ctsb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CTSB (Cathepsin B) encodes a cysteine protease that functions in protein degradation within lysosomes. Cathepsin B has been implicated in neurodegeneration through its role in amyloid-beta degradation, tau cleavage, and inflammatory responses. It represents both a therapeutic target and a potential biomarker.
| Property |
Value |
| Gene Symbol |
CTSB |
| Full Name |
Cathepsin B |
| Chromosomal Location |
8p23.1 |
| NCBI Gene ID |
1508 |
| Ensembl ID |
ENSG00000164733 |
| UniProt ID |
P07846 |
| OMIM |
116810 |
| Property |
Value |
| Protein Name |
Cathepsin B |
| Molecular Weight |
~38 kDa (339 amino acids) |
| Subcellular Localization |
Lysosomes, endosomes |
| Protein Family |
Cysteine cathepsin family (papain-like) |
¶ Domain Structure
- Signal peptide: Targeting to secretory pathway
- Propeptide (25 aa): Inhibits activity, removed in acidic environment
- Mature enzyme: Catalytic domain
- Occluding loop: Unique to cathepsin B, provides exopeptidase activity
- Lysosomal protease: Degrades proteins in lysosomes
- Protein turnover: Important for cellular protein homeostasis
- Autophagy: Role in autophagic-lysosomal degradation
- Extracellular matrix remodeling: Degrades ECM proteins
- Immune function: Antigen processing, MHC class II loading
- Amyloid-beta degradation: Cathepsin B can degrade Aβ
- Therapeutic potential: Enhancing cathepsin B to clear Aβ
- Opposite role: May also generate Aβ fragments via cleavage
- Genetic variants may modify AD risk
- Lysosomal dysfunction in PD
- Cathepsin B may degrade alpha-synuclein
- Role in GBA-associated PD
- Amyotrophic Lateral Sclerosis: Altered expression
- Huntington's Disease: Effects on mutant huntingtin
- Multiple sclerosis: Demyelination role
- Overexpression in various cancers
- Role in tumor invasion and metastasis
| Approach |
Status |
Description |
| Cathepsin B inhibitors |
Research |
For cancer, not AD (may impair Aβ clearance) |
| Cathepsin B activators |
Research |
Enhance Aβ clearance in AD |
| Gene therapy |
Preclinical |
Increase CTSB expression |
| None approved |
— |
No clinical trials for neurodegeneration |
- Hook VY, et al. (2008). Cathepsin B is a new drug target for neurodegenerative diseases. Drug News Perspect. 21(9):470-6. https://doi.org/10.1358/dnp.2008.21.9.1272060
- Mueller-Steiner S, et al. (2006). Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 51(6):703-14. https://doi.org/10.1016/j.neuron.2006.07.027
- Wolfe DM, et al. (2010). Autophagy failure in Alzheimer's disease and the role of the lysosomal system. Exp Neurol. 226(2):245-53. https://doi.org/10.1016/j.expneurol.2010.08.001
- Cataldo AM, et al. (1997). Gene expression and cellular sources of lysosomal cathepsins B and L in Alzheimer's disease. Neurobiol Aging. 18(1):S137. https://doi.org/10.1016/s0197-4580(97)00069-8
The study of Ctsb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cathepsin B and neurodegeneration. PMID:15630145